The Debiopharm Group and Marina Biotech, Inc. announced that they entered into an exclusive agreement concerning the development and commercialization of Marina Biotech's pre-clinical program in bladder cancer.

Debiopharm and Marina Biotech will work together to advance to market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer. Debiopharm will have full responsibility for the development and commercialization of any products arising from the partnership. Under the terms of the agreement, Debiopharm will pay Marina Biotech up to USD 25 million based on predefined research and development milestones as well as royalties on the sales of products resulting from the partnership. In addition, all Marina Biotech research and development costs for the bladder cancer program will be funded by Debiopharm beginning in February 2011. Further terms of the agreement were not disclosed.

Source:

Marina Biotech, Inc.; Debiopharm S.A.